2022 World Conference on Lung Cancer (ePosters)-EP01.03-010. China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results

EP01.03-010. China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results

Pdf Summary

The China Lung Cancer Screening Study (CLUS) version 2.0 was conducted to validate the effectiveness of low-dose computed tomography (LDCT) in detecting early-stage lung cancer and explore new techniques for lung cancer screening. The study was conducted from 2018 to 2019 and involved eligible participants with high-risk factors for lung cancer.<br /><br />Artificial intelligence was utilized in the screening process for high-risk subjects and in reading CT images. Positive screening results were identified if non-calcified nodules or masses with longest diameters of 5mm were detected on LDCT images. Participants who were heavy smokers were recommended to undergo Autofluorescence Bronchoscopy (AFB) detection, even if their LDCT images were negative. Circulating molecular biomarkers were used for lung cancer diagnosis.<br /><br />A total of 5087 high-risk participants were enrolled in the study, with 4395 undergoing LDCT detection. Of these, 857 participants (19.5%) had positive screening results. By December 2020, 77 patients had been diagnosed with lung cancer through operation or biopsy, including 70 cases of early-stage lung cancer (stage 0-I) and 6 cases of advanced-stage lung cancer (stage II-IV). Additionally, there was one case of a tracheobronchial tumor, one case of malignant pleural mesothelioma, and three cases of benign nodules. The study found that 91.4% of the diagnosed lung cancer cases were in early stages.<br /><br />The study concluded that LDCT screening is effective in detecting early-stage lung cancer and identified the potential for new techniques to enhance the implementation of LDCT screening.

Asset Subtitle

Fangfei Qian

Meta Tag

Speaker Fangfei Qian

Topic Early Detection and Screening - Implementation

Keywords

China Lung Cancer Screening Study

CLCS

low-dose computed tomography

LDCT

lung cancer screening

artificial intelligence

Autofluorescence Bronchoscopy

AFB

circulating molecular biomarkers

early-stage lung cancer